ALL INDIA INSITITUTE OF MEDICAL SCIENCES

RISHIKESH

Patient name: UHID: Admitted location:

Hospital Treatment Policy – "Plasma therapy" Information Sheet

(10.04.21 onwards)

Method of how to get the drug

While choosing any experimental therapy (CP, IFN, Tocilizumab, Remdesivir, etc) for any patient as per shared guidance flow chart, once treating faculty/SR decides the drug to be indented from sub-pharmacy/blood bank at own area, treating faculty/SR has to print this page, tick on the indication, cross on contra-indications, tick on each side effects/warnings after explaining to patient/relatives, write name of patient with UHID no and patient admitted location, sign this page, take another sign from one witness person (NO/doctor not treating this pt), sign on behalf of relative after telephonically consent obtained, then submit a copy at sub-pharmacy store/blood bank to obtain the drug for total doses and keep one copy with patient e-hospital file.

Indications in COVID-19:[1-4]

Presence of 1 or more of following selection criteria with symptom **onset <7days (mostly <3days) AND no positive/reactive IgG antibody against COVID-19**:

- Severe COVID-19:
  - Respiratory rate ≥ 30/min
  - SpO2 ≤ 93%,
  - PaO2/FiO2 ratio < 300
  - Lung infiltrates > 50% within 24 to 48 hours
- Life-threatening disease:
  - Respiratory failure
  - Septic shock
  - Multiple organ dysfunction or failure

Contraindications:

- Known moderate or severe allergy to blood components, plasma or ingredients (sodium citrate)
- Cases with serious general conditions, such as severe organ dysfunction
- Not willing to receive a blood product

Dose schedule & Administration:

Sign of treating faculty/SR *Sign of Patient care taker (consented)* Sign of Witness

@Dr. P. K. Panda (Nodal officer, Covid-19 Task Force, AIIMS Rishikesh, 9868999488)

Patient name: UHID: Admitted location:

- **One dose of 200 mL** of convalescent plasma (CP) derived from recently recovered ABO-compatible donor having **titres ≥250** followed **by another dose of 200 mL** of CP from another donor if possible (400 mL of CP in total) in a gap of 12-24hrs if first dose tolerated
- Administration: Intravenous infusion, **each dose over 2hrs**

Warnings/precautions:

- TRALI and TACO have been reported
- Fever, allergic reactions ranging from urticaria to anaphylaxis (rare)
- Transmission of infectious pathogens
- Antibody-mediated enhancement of infection
- Red cell alloimmunization

The efficacy and adverse effects associated with administration have not been well established in pregnancy and children

Monitoring parameters:

- Monitor for transfusion related reactions

References:

1. Drug controller general of India and US Food and Drug Administration. Recommendations for investigational COVID-19 convalescent plasma.
2. Joyner MJ et al. Convalescent plasma antibody levels and the risk of death from COVID-19, New Eng J Med, 2021. 10.1056/NEJMoa2031893.
3. Agarwal A, et al. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial), Brit Med J, 2020 371:m3939 http://dx.doi.org/10.1136/bmj.m3939.
4. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov
5. https://www.idsociety.org/covid-19-real-time-learning-network/therapeutics-and-interventions/convalescent-plasma/

Sign of treating faculty/SR *Sign of Patient care taker (consented)* Sign of Witness